How Is PROCEPT BioRobotics (NASDAQ:PRCT) Expanding Its Surgical Robotics Footprint with 18% Revenue Growth?

• U.S. procedures exceeded 13,400, representing approximately 22% year-over-year growth, reflecting rising utilization of Aquablation therapy.

Sonal Goyal | 05 November 2026

What Could an FDA Meeting Mean for Solid Biosciences'(NASDAQ:SLDB) Accelerated Approval Pathway for SGT-003?

• A Type C meeting with the FDA is scheduled for late Q4 2026 to discuss a potentialAccelerated Approvalpathway for SGT-003

Sonal Goyal | 05 November 2026

• Cash and investments totaled $629.8 million as of September 30, 2026, with the AstraZeneca funds received subsequently

Sonal Goyal | 05 November 2026

• PAP therapy patients increased 37.5% year-over-year and 16.0% sequentially to 43,861, while sleep resupply patients grew 22.1% year-over-year

Sonal Goyal | 05 November 2026

• X4 initiated the 4STEPS Phase 2b trial to evaluate G-CSF dose reduction with mavorixafor, with first enrollment expected in Q1 2027

Sonal Goyal | 05 November 2026

• Record quarter of 119,672 scans, up 61% on the prior corresponding period, with SaaS products delivered at 724 sites globally

Sonal Goyal | 05 November 2026

• UnderlyingEarnings Per Sharerose 8.5% to 18.33 cents, while statutory EPS declined 24.1% to 12.36 cents

Sonal Goyal | 05 November 2026

• The company achieved its third US FDA approval with tentative approval of Scomara for facial angiofibromas in tuberous sclerosis.

Sonal Goyal | 05 November 2026

• FY27 adjusted EPS guidance was set at US158 to US170 cents, representing continuedEarningsgrowth.

Sonal Goyal | 05 November 2026

• The biosynthetic wound matrix achieved a 96% reduction in preparation time while delivering comparable clinical outcomes

Sonal Goyal | 05 November 2026